Polyphor - Termination of coverage
Edison Investment Research is terminating coverage on John Laing Group (JLG), Appreciate Group (APP) and Polyphor (POLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.Previously published reports can still be accessed via our website.
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections; the Outer Membrane Protein Targeting Antibiotics (OMPTA), which provides treatment options to treat infections caused by Gram-negative bacteria; POL6014 is inhaled elastase inhibitor for the treatment of Cystic Fibrosis and other neutrophilic lung diseases, as well as Balixafortide (POL6326) is a blocker of tumor growth and metastasis. The Company develops Macrocycle discovery platform, which includes library consisted of over 50,000 single, untagged, individually purified peptidic and non-peptidic macrocycles readily amenable to all screening formats, including binding, enzymatic, cellular, pathway and phenotypical.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.